Industrial Manufacturing Process and Synthesis Route for H-Tyr-Asp-OH

• Technical Focus: Optimized coupling strategies to minimize aspartimide formation and ensure high yield.
• Quality Assurance: Rigorous purification protocols achieving pharmaceutical-grade industrial purity.
• Supply Chain: Scalable production capabilities for bulk procurement with comprehensive COA documentation.

The production of high-quality peptide building blocks is critical for the successful development of therapeutic agents. Among these, N-L-Tyrosyl-L-aspartic acid, commonly referred to as H-Tyr-Asp-OH (CAS: 87085-11-8), serves as a vital intermediate in the assembly of complex bioactive sequences. The chemical structure, formally known as (S)-2-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-succinic acid, presents specific synthetic challenges due to the reactivity of the aspartic acid side chain. Ensuring a robust synthesis route is essential for maintaining consistency in downstream peptide synthesis, particularly in solid-phase applications where impurity propagation can compromise final drug substance quality.

At NINGBO INNO PHARMCHEM CO.,LTD., we prioritize technical precision in the production of dipeptide intermediates. Our facilities are equipped to handle the nuanced chemistry required for aspartyl-containing compounds, focusing on yield optimization and impurity control. This article details the technical considerations involved in the industrial manufacturing process of this compound, addressing coupling efficiency, protecting group strategies, and scale-up parameters relevant to pharmaceutical procurement.

Optimized Synthesis Route and Coupling Strategies

The chemical synthesis of Tyr-Asp dipeptides typically involves the condensation of protected tyrosine and aspartic acid derivatives. A primary concern in this synthesis route is the prevention of side reactions, specifically the formation of aspartimide derivatives. Aspartimide formation is a well-documented issue in peptide chemistry, often occurring during base-catalyzed deprotection steps or coupling reactions involving tertiary amines. This side reaction leads to succinimide ring closure, resulting in alpha- and beta-aspartyl isomers that are difficult to separate.

To mitigate these risks, industrial protocols often employ specific side-chain protecting groups that offer steric hindrance without compromising coupling efficiency. While standard tert-butyl esters are common, advanced manufacturing processes may utilize bulky tertiary alcohol-based esters to suppress base-catalyzed cyclization. The coupling reaction itself is frequently mediated by carbodiimides, such as dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIC), often in the presence of additives like HOBt or Oxyma Pure to reduce racemization.

Following the coupling step, the removal of N-terminal protecting groups (such as Fmoc or Z) must be performed under conditions that preserve the integrity of the peptide bond and the side-chain functionality. Hydrogenolysis is commonly used for Z-group removal, while piperidine-based solutions are standard for Fmoc deprotection. However, the concentration and exposure time must be strictly controlled to prevent degradation. Our manufacturing process integrates real-time monitoring via HPLC to ensure reaction completion before proceeding to purification, thereby maximizing overall yield.

Impurity Control and Industrial Purity Standards

Achieving high industrial purity is non-negotiable for peptide building blocks intended for pharmaceutical use. The presence of deletion sequences, diastereomers, or aspartimide by-products can significantly impact the purity profile of the final active pharmaceutical ingredient (API). Post-synthesis, the crude material undergoes rigorous purification, typically utilizing preparative reverse-phase high-performance liquid chromatography (RP-HPLC).

Quality control protocols involve detailed analysis using LC-MS to identify and quantify specific impurities. Key parameters include the ratio of alpha-to-beta aspartyl linkages and the absence of free amino acids resulting from hydrolysis. For buyers evaluating suppliers, requesting a comprehensive Certificate of Analysis (COA) is standard practice. This document should detail purity levels, residual solvent content, and heavy metal specifications. As a global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. adheres to strict quality management systems to ensure every batch meets these stringent criteria.

The table below outlines typical technical specifications for pharmaceutical-grade H-Tyr-Asp-OH:

Parameter	Specification	Test Method
CAS Number	87085-11-8	N/A
Molecular Formula	C13H16N2O6	N/A
Molecular Weight	296.28 g/mol	N/A
Purity (HPLC)	> 98.0%	Area Normalization
Appearance	White to Off-White Powder	Visual
Water Content	< 5.0%	Karl Fischer
Residual Solvents	Compliant with ICH Q3C	GC

Scale-Up Challenges and Bulk Procurement

Transitioning from laboratory-scale synthesis to industrial production introduces several engineering challenges. Solvent selection is critical; while dimethylformamide (DMF) and dichloromethane (DCM) are traditional choices, environmental regulations and safety concerns are driving a shift toward greener alternatives. Solvents must facilitate adequate resin swelling in solid-phase applications or ensure complete solubility in solution-phase reactions without complicating downstream removal.

Furthermore, the stability of reagents and intermediates during extended holding times must be validated to prevent decomposition in large-scale reactors. Filtration processes also require optimization to handle precipitates, such as dicyclohexylurea (DCU), which can clog filters and slow production cycles. Efficient washing protocols are essential to remove these by-products without excessive solvent consumption, directly impacting the bulk price and sustainability of the manufacturing process.

For procurement teams, securing a reliable supply chain is paramount. When sourcing high-purity H-Tyr-Asp-OH, buyers should verify the manufacturer's capacity for scale-up and their ability to maintain consistency across large batches. Lead times, packaging options, and logistical support are key commercial considerations alongside technical specifications.

Conclusion

The industrial production of H-Tyr-Asp-OH requires a sophisticated understanding of peptide chemistry, particularly regarding the suppression of aspartimide formation and the maintenance of stereochemical integrity. By employing advanced protecting group strategies and rigorous purification techniques, manufacturers can deliver intermediates that support the efficient synthesis of complex therapeutics. Partnering with an experienced supplier ensures access to materials that meet the demanding requirements of modern drug development.

For further technical data or to discuss custom synthesis requirements, contact our sales team to request a quote and sample COA. We are committed to supporting your project with high-quality building blocks and reliable bulk supply.